Affiliation:
1. Multi-omics Laboratory of Breast Diseases, West China Hospital, Sichuan University , Chengdu, Sichuan , China
Abstract
AbstractThe overexpression of membrane-bound complement regulatory proteins (mCRPs) on tumour cells helps them survive complement attacks by suppressing antibody-mediated complement-dependent cytotoxicity (CDC). Consequently, mCRP overexpression limits monoclonal antibody drug immune efficacy. CD55, an mCRP, plays an important role in inhibiting antibody-mediated CDC. However, the mechanisms regulating CD55 expression in tumour cells remain unclear. Here, the aim was to explore CD55-targeting miRNAs. We previously constructed an in vitro model comprising cancer cell lines expressing α-gal and serum containing natural antibodies against α-gal and complement. This was used to simulate antibody-mediated CDC in colon cancer cells. We screened microRNAs that directly target CD55 using LoVo and Ls-174T colon cell lines, which express CD55 at low and high levels, respectively. miR-132-3p expression was dramatically lower in Ls-174T cells than in LoVo cells. miR-132-3p overexpression or inhibition transcriptionally regulated CD55 expression by specifically targeting its mRNA 3ʹ-untranslated regions. Further, miR-132-3p modulation regulated colon cancer cell sensitivity to antibody-mediated CDC through C5a release and C5b-9 deposition. Moreover, miR-132-3p expression was significantly reduced, whereas CD55 expression was increased, in colon cancer tissues compared to levels in adjacent normal tissues. CD55 protein levels were negatively correlated with miR-132-3p expression in colon cancer tissues. Our results indicate that miR-132-3p regulates colon cancer cell sensitivity to antibody-mediated CDC by directly targeting CD55. In addition, incubating the LoVo human tumour cell line, stably transfected with the xenoantigen α-gal, with human serum containing natural antibodies comprises a stable and cheap in vitro model to explore the mechanisms underlying antibody-mediated CDC.
Funder
National Natural Science Foundation of China
Science & Technology Department of Sichuan Province
Publisher
Oxford University Press (OUP)
Subject
Immunology,Immunology and Allergy
Reference47 articles.
1. Antibody therapy of cancer;Scott;Nat Rev Cancer,2012
2. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance;Smith;Oncogene,2003
3. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy;Mendelsohn;Clin Cancer Res,1997
4. Monoclonal antibody strategies to block angiogenesis;Hicklin;Drug Discov Today,2001
5. Combination strategies to enhance antitumor ADCC;Kohrt;Immunotherapy,2012